This is a binary catalyst. No data is released yet, so there is no directional signal from this filing. Monitor the September 14 webcast for efficacy (weight loss %) and safety (CNS side effects) — peripherally restricted CB1 agonists have historically failed on CNS tolerability. If weight loss is competitive with GLP-1s (≥5% placebo-adjusted) without CNS issues, the stock could re-rate; a miss or safety flag would be damaging.
Price Chart
Executive Summary
Corbus Pharmaceuticals announced a conference call for September 14 to discuss topline Phase 1b data for CRB-913, its novel oral CB1 inverse agonist for obesity. While the readout schedule provides a near-term catalyst, the announcement itself contains no efficacy or safety results, leaving the stock direction binary on the forthcoming data release.
Key Facts
- Corbus will host a conference call on September 14, 2026, at 8:00 a.m. EDT to discuss topline data from the CANYON-1 Phase 1b study of CRB-913.
- CANYON-1 is a 16-week double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adults across three doses (20 mg, 40 mg, 60 mg) plus placebo.
- Dose titration was built into the design: all CRB-913 subjects started at 20 mg/day and titrated up to their assigned cohort dose.
- The call is two trading days from this press release (Monday) — a tight catalyst window.
- CRB-913 is a once-daily, highly peripherally restricted oral CB1 inverse agonist, positioned as an orthogonal obesity therapy beyond GLP-1/incretin classes.
Financial Impact
No financial data disclosed; binary catalyst tied to Phase 1b topline data on September 14.
Risk Factors
- Data is still pending; this is a pre-catalyst announcement, not results.
- CB1 inverse agonists have a history of CNS safety failures (rimonabant withdrawal), and peripheral restriction may not fully eliminate psychiatric risks.
- Early-stage (Phase 1b) data may not be statistically powered for efficacy — a 'positive' readout could still be noisy and fail to replicate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360504 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.33 | awaiting T+60 | — | $3.99 (−7.85%) |
Sep 30, 2026 26d ago | SC 13G | $6.34 | awaiting T+60 | — | $3.99 (−37.07%) |
Sep 22, 2026 4w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $3.99 (−49.33%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $3.99 (−60.42%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $3.99 (−58.04%) |
May 26, 2026 21w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $3.99 (−49.56%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $3.99 (−65.33%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $3.99 (−66.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers